Krop IE, Jegede O, Grilley-Olson JE, et al. The presence of CTCs, which are epithelial tumor cells, has been independently associated with worse survival in several types of cancer.4446 For example, in a prospective, multicenter, double-blind study, the number of CTCs in patients with untreated metastatic breast cancer correlated with shorter progression-free survival (PFS) and overall survival (OS).44 CTCs may also be a predictive biomarker for chemotherapy and immunotherapy.45,47 However, the use of CTCs in clinical practice has not been fully established.48 Finally, serial CTC analyses might enable real-time surveillance of the disease. Concussion. 2017. Huang GD, Bull J, Johnston McKee K, Mahon E, Harper B, Roberts JN. Recent advances in genomic sequencing and omics-based capabilities are uncovering tremendous therapeutic opportunities and rapidly transforming the field of cancer medicine. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Journal Metrics: Cancer Medicine. npj Digital Medicine: 15.357: 15.597: 3.126: 0.01291 . Garassino M, Rodriguez-Abreu D, Gadgeel S, et al. The timely changed papers number can highlight the development tendency of a research field from the bibliometric perspective. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. Federal government websites often end in .gov or .mil. Ca-A Cancer Journal for Clinicians is a journal covering the categories related to Hematology (Q1); Oncology (Q1).It is published by Wiley-Blackwell.The overall rank of Ca-A Cancer Journal for Clinicians is 1.ISSN of this journal is/are 15424863, 00079235.. Impact Score: 186.75 h-Index: 182 SJR: 56.204 Overall Ranking: 1 in other publications. Recent developments in molecular biology and information technology make P. Gabrielle Bertier, Jian Carrot-Zhang, Vassilis Ragoussis and Yann Joly. The index is based on the set of the scientist's . Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. Nature Cancer: 23.177: 23.190: 5.100: 0.00816: 10.883: . Autologous cells are being harvested and administered to patients after their expansion and activation. BMC Cancer | About - BioMed Central Precision Cancer Medicine is a journal published by AME Publishing Company. Q1 (green) comprises the quarter of the journals with the highest values, Q2 (yellow) the second highest values, Q3 (orange) the third highest values and Q4 (red) the lowest values. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process. Browse Journal. CAR T-cells are currently being evaluated in solid tumors.96,97. Frontiers in Oncology | Thoracic Oncology Impact Factor: 5.479. It means 3 articles of this journal have more than 3 number of citations. Michuda J, Igartua C, Taxter T, Bell JS, Pelossof R, White K. Transcriptome-based cancer type prediction for tumors of unknown origin. Only Open Access Journals Only SciELO Journals Only WoS Journals Not every article in a journal is considered primary research and therefore "citable", this chart shows the ratio of a journal's articles including substantial research (research articles, conference papers and reviews) in three year windows vs. those documents other than research articles, reviews and conference papers. Failure to match patients is attributed to (i) enrollment of individuals with end-stage disease, who deteriorate or die early; (ii) use of small gene panels that yield limited actionable alterations; (iii) delays in receiving and interpreting genomic results; and (iv) difficulty accessing targeted therapy drugs and/or limited drug availability. Govers C, Sebestyn Z, Coccoris M, Willemsen RA, Debets R. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. The management of our journal is a collaborative endeavor by the whole editorial team, featuring an active, widely respected, diverse, and representative Editorial Board. In 2022, many PCM authors make outstanding contributions to our journal. The complexity is amplified by the dynamic, Darwinian evolutionary character of cancer cells, which undergo sequential searches for mechanisms to escape environmental constraints. Cancer Medicine 2022-2023 - & Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/, Journal Impact Factor, https://clarivate.com/. The editor-in-chief is Stephen Tait (Institute of Cancer Sciences, University of Glasgow ). Sign up for the Nature Briefing newsletter what matters in science, free to your inbox daily. This article is part of Nature Outlook: Precision Oncology, an editorially independent supplement produced with the financial support of third parties. General Genetics and Molecular Biology and Oncology and Cancer Research. IS 2021 of Precision Cancer Medicine is 0.34. Meetings, IEEE Article More Details Precision Cancer Medicine impact factor and citations: | Exaly Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657, Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER), Adaptive Randomization of Neratinib in Early Breast Cancer, Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer, Unique molecular landscapes in cancer: implications for individualized, curated drug combinations, Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes, Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. AR-V7 and treatment selection in advanced prostate cancer: are we there yet? Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of cutting-edge research from global biomedical researchers across the cancer sciences. The h-index is a way of measuring the productivity and citation impact of the publications. Google Scholar. Technological, methodological, and analytical advances continue to improve the resolution of our view into the cancer genome, even as we discover ways to carry out analyses at greater distances from the primar Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large number of patients present with or develop resistance to them. The journal publishes basic and clinical trials studies which aim to promote personalized medicine, including novel technologies of cancer diagnosis, new drugs and . The Guest editors declare no competing interests. Cancer Medicine Key Factor Analysis. However, the point probably marking the revolution towards a precision medicine approach was the approval of imatinib in patients with chronic myeloid leukemia bearing the t (9,22) translocation that creates a BCR-ABL . Tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify these characteristics for optimization of anticancer therapy in individual patients. Aftimos PG, Antunes De Melo e Oliveira AM, Hilbers F, et al. scijournal.org is a platform dedicated to making the search and Cristofanilli M, Budd GT, Ellis MJ, et al. Genomic biomarkers have been the most successful to date, but other biomarkers, including protein assays and transcriptomics, are being developed and tested.13,24,25 Several molecular alterations have been identified using sequencing and high-throughput technologies and have led to the approval of targeted agents by the Food and Drug Administration (FDA).26,27 Importantly, in recent years, the precision medicine paradigm has embraced immunotherapy and its interaction with genomics, as genomic characteristics, such as mismatch repair gene defects, are critical predictors of checkpoint blockade response.2830. Genome Medicine is pleased to present a special issue on Precision Cancer Medicine. The two years line is equivalent to journal impact factor (Thomson Reuters) metric. Home - AME Medical Journal The Dalian Institute of Chemical Physics (DICP). Seminars Chodon T, Comin-Anduix B, Chmielowski B, et al. Therefore, the FDA has approved CAR T-cells for the treatment of pediatric patients and young adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (Kymriah, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma) and adult patients with relapsed/refractory diffuse large B-cell lymphoma (Yescarta, https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel). Precision Cancer Medicine (PCM, Precis Cancer Med, ISSN: 2617-2216) is an open access, peer-reviewed online journal dedicated to precise diagnosis and treatment of cancers and personalized care for patients. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? Transcriptomics are utilized to identify prognostic and predictive gene expression signatures50,51, to explore miRNAs and their role in mRNA regulation52,53 and to identify the tissue of origin in cancer of unknown primary.5456 The first solid tumor precision medicine trial to use transcriptomics in the clinic--WINTHER---compared RNA expression in tumors to that in adjacent normal tissue and demonstrated that transcriptomics increased the number of patients that could be matched to therapy.13 Comparing tumor to normal tissue from the same patient may be necessary because of the large inter-patient variability in normal RNA expression. In 2001, the human genome was sequenced.33 Although this milestone represented an arduous and tremendously expensive endeavour, both the price and time required for sequencing have decreased precipitously, with technology advancing in a manner unparalleled in human history. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers. Impact Factor. The best quartile for this journal is Q3. The chart shows the ratio of a journal's documents signed by researchers from more than one country; that is including more than one country address. In this review, we summarize the clinical trials and discuss challenges and opportunities to accelerate the implementation of precision oncology. Jacobsen A, Silber J, Harinath G, Huse JT, Schultz N, Sander C. Analysis of microRNA-target interactions across diverse cancer types. Journal Metrics | Nature Portfolio We look forward to your submission. Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy. This journal covers the area [s] related to Anesthesiology and Pain Medicine, Pharmacology (medical), Surgery, Cancer Research, Oncology, Oncology (nursing), etc . Careers, Unable to load your collection due to an error. The coverage history of this journal is as follows: 2018-2021. An article for this column could be a Case-Based Review, providing a case with educational values and relevant review of the literature and highlighting the level of evidence supporting key decisions. Follow us on @ScimagoJRScimago Lab, Copyright 2007-2022. Through this web page, researchers can check the impact factor, total citation, journal quartile, and journal aim & scope. Beyond genomics, RNA and protein profiling, with proteins being the effectors of signaling, also appear to be important in mediating biologic impact. Review of Precision Cancer Medicine: Evolution of the Treatment Journal Information | British Journal of Cancer - Nature How Influential is Precision Cancer Medicine? Precision Cancer Medicine - SCI Journal To overcome the complexity of tumor biology, clinical trials with combinations of gene-targeted therapy with immune-targeted approaches (e.g., checkpoint blockade, personalized vaccines and/or chimeric antigen receptor T-cells), hormonal therapy, chemotherapy and/or novel agents should be considered. . useof impact factors of science journals easier. Schwaederle M, Parker BA, Schwab RB, et al. You can start . Journal Matcher. (Accessed The RNA and protein landscape that could bring precision medicine to more people, Health-care inequality could deepen with precision oncology, The gene-therapy revolution risks stalling if we dont talk about drug pricing, Unleashing the power of big data to guide precision medicine in China, Early prediction of preeclampsia in pregnancy with cell-free RNA, Patterns of tumour transcriptional variability, In situ tumour arrays reveal early environmental control of cancer immunity, Pan-KRAS inhibitor disables oncogenic signalling and tumour growth, Why the world needs more transparency on the origins of novel pathogens, A fat-blocking drug could help to fight metastatic cancer. Wiley Cancer Medicine Journal's Impact IF Prediction System is now online. . Precision Medical Sciences is an international and peer-reviewed open access journal that covers all areas of clinical and translational research for precision medicine, especially in the field of oncology. It is time to recognize the possibility that advanced computer implementation could generate real-world data that expand our understanding of cancer, rapidly identify new treatments, and create personalized drugs or immune therapies. Research efforts to discover effective combination treatments have f To truly achieve personalized medicine in oncology, it is critical to catalog and curate cancer sequence variants for their clinical relevance. The clinical integration of genome sequencing into standard clinical practice has b Comprehensive genomic sequencing (CGS) has the potential to revolutionize precision medicine for cancer patients across the globe. Citations. [] From 2012 to 2021, the number of annual publications on oncology precision grew year by year as shown in Figure 2.From the figure, only 12 (0.17%) papers were published in 2012, while it increased 126.75 . Precision Cancer Medicine - Impact Factor, Overall Ranking, Rating, h Cancer Medicine Key Factor Analysis. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. About this Journal. Bridgewater J, van Laar R, Floore A, VanT Veer L. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary, Development and validation of a gene expression tumour classifier for cancer of unknown primary. We are pleased to announce that the Translational Cancer Research (TCR) has attained its latest impact factor update for the 2020 citation year: 1.241.. Translational Cancer Research (Transl Cancer Res, TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). Standard methods use statistically significant recurrence of mutations in tumor samples as an indicator of functional impact. 2022 www.resurchify.com All Rights Reserved. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work. Full implementation of transparent peer review at Precision Cancer Medicine (PCM), The Belt and Road International Forum for Precision Radiation Oncology, Annals of Laparoscopic and Endoscopic Surgery, Frontiers of Oral and Maxillofacial Medicine, Journal of Emergency and Critical Care Medicine, Journal of Hospital Management and Health Policy, Journal of Laboratory and Precision Medicine, Journal of Medical Artificial Intelligence, Journal of Oral and Maxillofacial Anesthesia, Pharmacogenomics Research and Personalized Medicine, Quantitative Imaging in Medicine and Surgery, Translational Gastroenterology and Hepatology. This complexity is attributed to highly variable patterns of genetic and epigenetic diversity and clonal architecture associated with spatial expansion, proliferative self-renewal, migration, and invasion. JCO Precision Oncology - Scimago Journal & Country Rank The rise of genomically targeted therapies and immunotherapy has revolutionized the practice of oncology in the last 1015 years. As there are several TKIs, upon progression, the optimal sequential ALK and ROS-1 TKI strategy at progression is relevant, and this may have an impact on patients' outcome. Published: 2022-06-30. If your research field is/are related to Anesthesiology and Pain Medicine (Q3); Pharmacology (medical) (Q3); Surgery (Q3); Cancer Research (Q4); Oncology (Q4); Oncology (nursing) (Q4), then In the meantime, to ensure continued support, we are displaying the site without styles Ratio of a journal's items, grouped in three years windows, that have been cited at least once vs. those not cited during the following year. Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine. Precision Medical Sciences - Wiley Online Library PCR-based genomics and NGS, 11 to 182 genes, PFS not improved with matched therapy (p=0.41), ~80% of patients received single-agent hormone modulators or everolimus, MD Anderson Personalized Cancer Therapy Initiative, Higher matching scores correlated with higher rates of SD 6 months/PR/CR (p=0.024), TTF (p=0.0003), and OS (p=0.05), 251 patients enrolled; 230 were treated; however, how many were screened pre-enrollment is unknown, Higher matching scores correlated with increased rates of SD6 months/PR/CR: 50% vs 22.4% (p=0.028), PFS (p=0.0004), and OS (p=0.038), University of California San Diego and Avera, First trial to administer customized combination therapy (N-of-1 matching), Higher matching scores correlated with longer PFS (p=0.005) and OS (p= 0.03), Five countries (Spain, Israel, France, Canada, US), First solid tumor trial to include transcriptomics, It is unclear how many patients were screened before consent, Improved OS with matched vs unmatched therapy (p=0.006), Improved survival with matched therapy (p<0.001), ALK, FISH, EGFR, and KRAS Sanger sequencing, Aim was to develop biomarkers of response to conventional therapy. It is published by AME Publishing Company. Chabon JJ, Simmons AD, Lovejoy AF, et al. The series on Quality Assurance in Radiotherapy is edited by Drs Paul Van Houtte and Dirk Van Gestel (Institut Jules Bordet, Belgium). The identification of functional non-coding mutations is a key challenge in the field of genomics. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children, Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match, A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia, The molecular genetics of Philadelphia chromosome-positive leukemias, Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400, Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. A major challenge in the therapeutic management of patients with advanced metastatic cancer is the complexity of tumor biology. But, as some people with cancer are already finding out, there is another way.
Kpj Cataract Surgery Cost, Articles P